cepharanthine has been researched along with Autoimmune Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Hirano, T; Onda, K; Sugiyama, K; Tanaka, S; Wang, X; Xu, W; Yamada, H | 1 |
| Byun, S; Lee, E; Lee, KW | 1 |
| Fukuhara, S; Kagawa, H; Matsuzaki, T; Nagahama, M; Nakayama, S; Nomura, S; Ozaki, Y; Yamaoka, M; Yoshimura, C | 1 |
2 review(s) available for cepharanthine and Autoimmune Disease
| Article | Year |
|---|---|
Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autoimmune Diseases; Benzylisoquinolines; Cell Cycle; Down-Regulation; Drug Therapy, Combination; Glucocorticoids; Humans; Mitogen-Activated Protein Kinases; NF-kappa B; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction; T-Lymphocytes; TOR Serine-Threonine Kinases | 2021 |
Therapeutic Implications of Autophagy Inducers in Immunological Disorders, Infection, and Cancer.
Topics: Adaptive Immunity; Animals; Autoimmune Diseases; Autophagy; Benzylisoquinolines; Cholecalciferol; Humans; Immune System Diseases; Immunity, Innate; Indoles; Infections; Isoquinolines; Lysosomes; Maprotiline; Metformin; Neoplasms; Phenols; Pyrroles; Resveratrol; Sirolimus; Spermidine; Stilbenes; Tetrahydroisoquinolines; Trehalose | 2017 |
1 other study(ies) available for cepharanthine and Autoimmune Disease
| Article | Year |
|---|---|
Genetic analysis of HLA- and HPA-typing in idiopathic (autoimmune) thrombocytopenic purpura patients treated with cepharanthin.
Topics: Adult; Aged; Alkaloids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Human Platelet; Autoantigens; Autoimmune Diseases; Benzylisoquinolines; Blood Platelets; Combined Modality Therapy; Drug Resistance; Endocytosis; Female; Genetic Predisposition to Disease; Genotype; HLA Antigens; HLA-DQ Antigens; HLA-DQ beta-Chains; HLA-DR Antigens; HLA-DRB1 Chains; Humans; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single-Stranded Conformational; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Splenectomy; Treatment Outcome | 1999 |